Prurigo nodularis
| Prurigo nodularis | |
|---|---|
| Other names | Hyde's disease, nodular prurigo |
| Prurigo nodularis lesions on the legs, arms, and trunk of a patient | |
| Nodular lesions on the lateral surface of a patient's hand | |
| Specialty | Dermatology |
| Symptoms | Firm, symmetrically distributed nodules or papules with paroxysmal intense chronic pruritus |
| Complications | Anxiety, depression, sleep disturbances, secondary bacterial infection |
| Usual onset | Adulthood or advanced age |
| Duration | Chronic, refractory, and prone to recurrence |
| Types | Classified by lesion count: mild (<20), moderate (20–99), severe (≥100) |
| Causes | The interaction of three links: primary epidermal barrier defect, type II immune inflammation, and neural structural remodeling. |
| Risk factors | Advanced age, female sex, Black ethnicity, diabetes mellitus, peripheral neuropathy, chronic kidney disease |
| Diagnostic method | Morphology of skin lesions (texture, size), distribution pattern (extensor limbs, butterfly sign) |
| Differential diagnosis | Dermatitis, Lichen planus, Bullous pemphigoid, Scabies |
| Prevention | Avoid scratching and friction, intensive gentle moisturization, avoidance of triggers |
| Treatment | Conventional medications, physical therapies, and biologic agents |
| Medication | Corticosteroids, immunosuppressive drugs, biologic agents |
| Frequency | Global prevalence approximately 0.083% |
Prurigo nodularis (PN) is a chronic, inflammatory skin disease characterized by intense pruritus and symmetrically distributed, firm papules or nodules on the skin. The core pathogenesis of PN involves a three-stage model comprising primary epidermal barrier defect, type 2 immune inflammation, and neural structural remodeling.
Clinically, the diagnosis of PN relies on the characteristic morphology of skin lesions, their distinctive anatomical distribution, and the pattern of chronic severe pruritus. Epidemiological data indicate that the global prevalence of PN is approximately 0.083%, predominantly affecting adults and the elderly, with higher incidence rates observed in females and individuals of Black ethnicity.
Treatment of PN follows a multimodal, stepwise approach, ranging from topical corticosteroids and phototherapy to biologic agents targeting the type 2 inflammatory pathway. Because PN is frequently associated with systemic diseases (such as diabetes and renal disease), peripheral neuropathy, and psychiatric comorbidities (anxiety and depression), effective clinical management requires simultaneous addressing of skin lesions, neurological symptoms, and psychosocial factors in order to interrupt the persistent itch-scratch cycle.